Cargando…

349. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19

BACKGROUND: Patients with COVID-19 receive high rates of antibiotic therapy, despite viral origin of infection. Reports of bacterial coinfection range from 3.5 to 8% in the early phase of infection. This study aimed to evaluate the relationship between diagnostic tests and antibiotic utilization in...

Descripción completa

Detalles Bibliográficos
Autores principales: Groft, Lauren, Opran, Iulia, Tadesse, Yeabsera, Vo, Hang, Heil, Emily, Schrank, Gregory, Claeys, Kimberly C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643796/
http://dx.doi.org/10.1093/ofid/ofab466.550
_version_ 1784609935726739456
author Groft, Lauren
Opran, Iulia
Tadesse, Yeabsera
Vo, Hang
Heil, Emily
Heil, Emily
Schrank, Gregory
Claeys, Kimberly C
author_facet Groft, Lauren
Opran, Iulia
Tadesse, Yeabsera
Vo, Hang
Heil, Emily
Heil, Emily
Schrank, Gregory
Claeys, Kimberly C
author_sort Groft, Lauren
collection PubMed
description BACKGROUND: Patients with COVID-19 receive high rates of antibiotic therapy, despite viral origin of infection. Reports of bacterial coinfection range from 3.5 to 8% in the early phase of infection. This study aimed to evaluate the relationship between diagnostic tests and antibiotic utilization in patients admitted with COVID-19 at the University of Maryland Medical Center to better inform future prescribing practices. METHODS: Retrospective cohort study of adult patients with a positive SARS-CoV-2 PCR on admission from March 2020 through June 2020. Associations between diagnostic tests employed and antibiotic initiation and duration were explored using bivariate analysis (SPSS®). RESULTS: Baseline characteristics of 224 included patients are reported in Table 1. Excluding SARS-CoV-2 PCRs, most frequently performed diagnostic tests included blood cultures (65.6%), MRSA nasal surveillance (45.1%), respiratory cultures (36.2%), respiratory viral panel (RVP) (33.0%), and Legionella (28.6%) and pneumococcal (26.3%) urine antigens. Positivity of RVP, Legionella, pneumococcus, blood, and respiratory tests were low (1.3%, 0.4%, 0.9%, 1.8%, and 6.7%, respectively). A total of 62% of patients were initiated on antibacterial therapy with a median cumulative antibiotic duration of 77.9 hours (IQR 41.4, 111.8). History of chronic respiratory disease (76% vs. 58.6%; P=0.025), any degree of oxygen requirement on admission (72% vs. 42.6%; P=0.006), and performance of blood cultures (70.7% vs. 46.8%, P< 0.0001) were associated with antibiotic initiation. Positive bacterial diagnostic respiratory culture (median duration 72.8h [IQR 46.7, 96.6] vs. 97.3h [IQR 79.8, 194.1]; P=0.027) and positive blood culture (median duration 80.1h [IQR 42.1, 111.7] vs. 97.5h [IQR 71.8, 164.8]; P=0.046) were associated with longer antibiotic duration. Patients who did not have respiratory cultures performed had similar antibiotic durations as those with negative respiratory cultures. Table 1. Baseline Characteristics [Image: see text] CONCLUSION: Despite low coinfection rates, negative diagnostic tests did not result in shorter empiric antibacterial duration. These findings highlight the ongoing need for both diagnostic and antimicrobial stewardship in COVID-19. DISCLOSURES: Emily Heil, PharmD, MS, BCIDP, Nothing to disclose Kimberly C. Claeys, PharmD, GenMark (Speaker’s Bureau)
format Online
Article
Text
id pubmed-8643796
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86437962021-12-06 349. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19 Groft, Lauren Opran, Iulia Tadesse, Yeabsera Vo, Hang Heil, Emily Heil, Emily Schrank, Gregory Claeys, Kimberly C Open Forum Infect Dis Poster Abstracts BACKGROUND: Patients with COVID-19 receive high rates of antibiotic therapy, despite viral origin of infection. Reports of bacterial coinfection range from 3.5 to 8% in the early phase of infection. This study aimed to evaluate the relationship between diagnostic tests and antibiotic utilization in patients admitted with COVID-19 at the University of Maryland Medical Center to better inform future prescribing practices. METHODS: Retrospective cohort study of adult patients with a positive SARS-CoV-2 PCR on admission from March 2020 through June 2020. Associations between diagnostic tests employed and antibiotic initiation and duration were explored using bivariate analysis (SPSS®). RESULTS: Baseline characteristics of 224 included patients are reported in Table 1. Excluding SARS-CoV-2 PCRs, most frequently performed diagnostic tests included blood cultures (65.6%), MRSA nasal surveillance (45.1%), respiratory cultures (36.2%), respiratory viral panel (RVP) (33.0%), and Legionella (28.6%) and pneumococcal (26.3%) urine antigens. Positivity of RVP, Legionella, pneumococcus, blood, and respiratory tests were low (1.3%, 0.4%, 0.9%, 1.8%, and 6.7%, respectively). A total of 62% of patients were initiated on antibacterial therapy with a median cumulative antibiotic duration of 77.9 hours (IQR 41.4, 111.8). History of chronic respiratory disease (76% vs. 58.6%; P=0.025), any degree of oxygen requirement on admission (72% vs. 42.6%; P=0.006), and performance of blood cultures (70.7% vs. 46.8%, P< 0.0001) were associated with antibiotic initiation. Positive bacterial diagnostic respiratory culture (median duration 72.8h [IQR 46.7, 96.6] vs. 97.3h [IQR 79.8, 194.1]; P=0.027) and positive blood culture (median duration 80.1h [IQR 42.1, 111.7] vs. 97.5h [IQR 71.8, 164.8]; P=0.046) were associated with longer antibiotic duration. Patients who did not have respiratory cultures performed had similar antibiotic durations as those with negative respiratory cultures. Table 1. Baseline Characteristics [Image: see text] CONCLUSION: Despite low coinfection rates, negative diagnostic tests did not result in shorter empiric antibacterial duration. These findings highlight the ongoing need for both diagnostic and antimicrobial stewardship in COVID-19. DISCLOSURES: Emily Heil, PharmD, MS, BCIDP, Nothing to disclose Kimberly C. Claeys, PharmD, GenMark (Speaker’s Bureau) Oxford University Press 2021-12-04 /pmc/articles/PMC8643796/ http://dx.doi.org/10.1093/ofid/ofab466.550 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Abstracts
Groft, Lauren
Opran, Iulia
Tadesse, Yeabsera
Vo, Hang
Heil, Emily
Heil, Emily
Schrank, Gregory
Claeys, Kimberly C
349. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19
title 349. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19
title_full 349. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19
title_fullStr 349. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19
title_full_unstemmed 349. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19
title_short 349. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19
title_sort 349. diagnostic testing and antibiotic utilization in patients with covid-19
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643796/
http://dx.doi.org/10.1093/ofid/ofab466.550
work_keys_str_mv AT groftlauren 349diagnostictestingandantibioticutilizationinpatientswithcovid19
AT opraniulia 349diagnostictestingandantibioticutilizationinpatientswithcovid19
AT tadesseyeabsera 349diagnostictestingandantibioticutilizationinpatientswithcovid19
AT vohang 349diagnostictestingandantibioticutilizationinpatientswithcovid19
AT heilemily 349diagnostictestingandantibioticutilizationinpatientswithcovid19
AT heilemily 349diagnostictestingandantibioticutilizationinpatientswithcovid19
AT schrankgregory 349diagnostictestingandantibioticutilizationinpatientswithcovid19
AT claeyskimberlyc 349diagnostictestingandantibioticutilizationinpatientswithcovid19